MF59™-adjuvanted seasonal influenza vaccine in young children

The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells

(2014) A. Seubert et al.   JOURNAL OF IMMUNOLOGY

"Herd Immunity": A Rough Guide

(2011) P. Fine et al.   CLINICAL INFECTIOUS DISEASES

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

(2011) Angelika Banzhoff et al.   Human vaccines & immunotherapeutics

The Population Impact of a Large School-Based Influenza Vaccination Campaign

(2011) Carlos G. Grijalva et al.   PLoS One

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

(2011) Theodore F. Tsai et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes

(2011) Samuele Calabro et al.   VACCINE

2009 Pandemic Influenza A (H1N1) Deaths among Children—United States, 2009–2010

(2010) Chad M. Cox et al.   CLINICAL INFECTIOUS DISEASES

Influenza Vaccination of Children and Infection Rates in the Community

(2010) Parker A. Small   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Influenza Vaccination of Children on Infection Rates in Hutterite Communities

(2010) Mark Loeb et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Burden of Seasonal Influenza Hospitalization in Children, United States, 2003 to 2008

(2010) Fatimah S. Dawood et al.   JOURNAL OF PEDIATRICS

Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study

(2010) Santtu Heinonen et al.   LANCET INFECTIOUS DISEASES

Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus

(2010) S. Khurana et al.   Science Translational Medicine

Effectiveness of seasonal 2008–2009, 2009–2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case–control study

(2010) Joan Puig-Barberà et al.   VACCINE

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis

(2010) Steven Black et al.   VACCINE

Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database

(2009) Michele Pellegrini et al.   VACCINE

Emerging Data on the Safety and Efficacy of Influenza Vaccines in Children

(2008) Timo Vesikari   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Molecular and cellular signatures of human vaccine adjuvants

(2008) F. Mosca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and efficacy of live attenuated influenza vaccine in children 2–7 years of age

(2008) Robert B. Belshe et al.   VACCINE

Safety of MF59™ adjuvant

(2008) Viola Schultze et al.   VACCINE

Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases

(2008) Joël Mossong et al.   PLOS MEDICINE